LIST OF CLINICAL TRIALS THAT ARE CURRENTLY RECRUITING PARTICIPANTS

Updated as of March 27, 2019

For studies that are active but not recruiting participants, please contact the Clinical Research Center. This list does not include studies under the Cellular Therapeutics Center.
 

Active Cutaneous Lupus Erythematosus
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations  and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations

Principal Investigator:   Dr. Jose Paulo Lorenzo
Co-Investigator:              Dr. Andrei Rhoneil Rodriguez

Learn More

 

Breast Cancer
A Randomize, Double-blind, Parallel-group, Phase III trial to Compare the Efficacy, Safety, and Immunogenicity of TX-05 with Herceptin® in subjects with HER2 Positive Early Breast Cancer

Principal Investigator:   Dr. Regina Edusma-Dy

Learn More


Cervical Cancer
A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with and following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer (CALLA)

Principal Investigator:   Dr. Teresa Sy-Ortin

Learn More



Conjunctivitis
A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine and Placebo in the Treatment of Adenoviral/Bacterial Conjunctivitis

Principal Investigator:   Dr. Edward Uy

Learn More


Diabetes Mellitus 
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents with Type 2 Diabetes

Principal Investigator:    Dr. Sylvia Capistrano-Estrada


Learn More


Liver Cancer
Phase 1 Dose Escalation Trial to evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Reximmune-C2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes) in Refractory patients with primary Hepatocellular Carcinoma or Tumors Metastatic to the Liver

Principal Investigator:   Dr. Maria Belen Tamayo
Co-Investigator:              Dr. Regina Edusma-Dy
 

Lung Cancer


A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently with Platinum-based Chemoradiation Therapy in Patients with Locally Advanced, Unresectable, Non-small Cell Lung Cancer (Stage III)

Principal Investigator:   Dr. Barbara Domingo

Learn More

A Randomized , Double Blind, Placebo Controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-Based Double Chemotherapy with or without Canakinumab as First Line Therapy for Locally Advanced of Metastatic Non Squamous and Non Small Cell Lung Cancer Subject (CANOPY-1U)

Principal Investigator:   Dr. Joseph Parra

Learn More


Neurogenic Detrusor Overactivity
A 24-Week Randomized, Open-Label, Study to Evaluate The Safety And Efficacy Of Fesoterodine in Subjects Aged 6 to 17 Years with Symptoms of Detrusor Overactivity Associated with a Neurological Condition (Neurogenic Detrusor Overactivity)

Principal Investigator:   Dr. Jose Dante Dator
Co-Investigator:              Dr. Carlos Ramon Torres

Learn More


Pulmonary Arterial Hypertension
A Multicenter, Open-Label, Randomized, Event-Driven Study to Assess Efficacy, Safety and Pharmacokinetics of Macitentan versus Standard of Care in Children with Pulmonary Arterial Hypertension.

Principal Investigator:   Dr. Aurelia Leus
Co-Investigator:              Dr. Rozaida Villon

Learn More


Urothelial Cancer
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer (NILE)

Principal Investigator:   Dr. Maria Belen Tamayo

Learn More